Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
CAMBRIDGE, Mass., April 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024, to report its first quarter 2024 financial results and provide a corporate update.
馬薩諸塞州劍橋，2024年4月18日 /PRNewswire/ — Blueprint Medicines Corporation（納斯達克股票代碼：BPMC）今天宣佈，它將在美國東部時間2024年5月2日星期四上午8點舉行電話會議和網絡直播，以報告其2024年第一季度財務業績並提供公司最新情況。
To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 186292. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.
要觀看電話會議，請撥打 833-470-1428（國內）或 404-975-4839（國際），並參考會議編號186292。電話會議的網絡直播也將在Blueprint Medicines網站的 “投資者與媒體” 部分的 “活動和演講” 下播出。存檔的網絡直播將在電話會議結束大約兩個小時後在Blueprint Medicines的網站上播出，並將在電話會議結束後的30天內播出。
About Blueprint Medicines
關於《藍圖藥品》
Blueprint Medicines is a fully integrated, commercial-stage, global biopharmaceutical company that invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. We pursue discovery, development, and commercialization of therapies that potently and selectively target known drivers of disease, with focused investment in therapeutic areas where we can leverage our core expertise and business infrastructure to bring scale to our science. We are bringing AYVAKIT/AYVAKYT (avapritinib) to people living with systemic mastocytosis (SM) in the U.S. and Europe. Additionally, we have a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including SM and chronic urticaria, and oncology including breast cancer, and other solid tumors vulnerable to CDK2 inhibition. For more information, visit and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.
Blueprint Medicines是一家完全整合的、處於商業階段的全球生物製藥公司，在過敏/炎症和腫瘤學/血液學這兩個核心戰略領域發明了改變生活的藥物。我們致力於發現、開發和商業化能夠有效和有選擇地針對已知疾病驅動因素的療法，重點投資於治療領域，在這些領域我們可以利用我們的核心專業知識和業務基礎設施來擴大我們的科學規模。我們帶來了 AYVAKIT/AYVAKYT （阿伐替尼）適用於美國和歐洲的系統性肥大細胞增多症（SM）患者。此外，我們還有一系列研發項目，從早期科學到高級臨床試驗，涉及肥大細胞介導的疾病，包括SM和慢性蕁麻疹，以及包括乳腺癌在內的腫瘤學以及其他易受CDK2抑制的實體瘤。欲了解更多信息，請在 X（前身爲 Twitter；@BlueprintMeds）和 LinkedIn 上訪問並關注我們。
SOURCE Blueprint Medicines Corporation
來源 Blueprint
譯文內容由第三人軟體翻譯。